Reference tissue normalization in longitudinal 18F-florbetapir positron emission tomography of late mild cognitive impairment

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages

  Shokouhi, Sepideh ^a   McKay, John W ^a   Baker, Suzanne L ^b   Kang, Hakmook ^c   Brill, Aaron B ^a   Gwirtsman, Harry E ^c   Riddle, William R ^a   Claassen, Daniel O ^a   Rogers, Baxter P ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-41); ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; PEPTIDE FRAGMENT;

AGED; ANALYTICAL PARAMETERS; ARTICLE; BRAIN STEM; CEREBELLUM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORPUS CALLOSUM; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REFERENCE TISSUE NORMALIZATION; STANDARDIZED UPTAKE VALUE RATIO; WHITE MATTER; BRAIN; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; LONGITUDINAL STUDY; METABOLISM; PROCEDURES; REPRODUCIBILITY; STANDARD;

AGED; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; COGNITIVE DYSFUNCTION; ETHYLENE GLYCOLS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 84954118996     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0172-3     Document Type: Article

References (41)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-59.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-6. A published erratum appears in Science. 2002;297:2209.
3. Thal DR, Rüb U, Orantes M, Braak H. Phase of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-800.
4. Jagust WJ, Mormino EC. Lifespan brain activity, β-amyloid, and Alzheimer's disease. Trends Cogn Sci. 2011;15:520-6.
5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
6. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9:e111-94.
7. Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov. 2013;12:324.
8. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820-5.
9. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19.
10. 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med. 2009;50:1887-94.
11. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and β-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.
12. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129-35.
13. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818-22.
14. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol. 1989;135:309-19.
15. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-45.
16. Cohen AD, Rabinovici GD, Mathis CA, Jagust WJ, Klunk WE, Ikonomovic MD. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-β. Adv Pharmacol. 2012;64:27-81.
17. Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26:8-16.
18. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med. 2011;52:1733-40.
19. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959-72.
20. 18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450-9.
21. Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560-6.
22. 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567-74.
23. 18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging. 2010;37:575-88.
24. Shokouhi S, Rogers BP, Kang H, Ding Z, Claassen DO, Mckay JW, et al. Modeling clustered activity increase in amyloid-β positron emission tomographic images with statistical descriptors. Clin Interv Aging. 2015;10:759-70.
25. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9:251-61.
26. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-64.
27. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
28. Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517-27.
29. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-7.
30. Peebles PJE. The large scale structure of the universe. Princeton, NJ: Princeton University Press; 1980.
31. Torquato S. Random heterogeneous materials: microstructure and macroscopic properties. New York: Springer; 2002.
32. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid β-peptide from brain: transport or metabolism? Nat Med. 2000;6:718-9.
33. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11:1048-56.
34. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One. 2009;4:e6294.
35. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS amyloid-β in Alzheimer's disease. Science. 2010;330:1774.
36. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193-9.
37. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013;74:826-36.
38. Boellaard R, Oyen WJG, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320-33.
39. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission computed tomography core. Alzheimers Dement. 2010;6:221-9.
40. Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11:1050-68.
41. Klein G, Sampat M, Staewen D, Scott D, Suhy J. Effect size and spatial smoothing of ADNI florbetapir and FDG PET. Washington, DC, USA: Poster presented at the Alzheimer's Association International Conference (AAIC); 2015.